Загрузка...
Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
BACKGROUND: Effects of roflumilast on lung function, symptoms, acute exacerbation and adverse events in patients with chronic obstructive pulmonary disease (COPD) are controversial. We aimed to further clarify the efficacy and safety of roflumilast in treatment of moderate-to-severe COPD. METHODS: F...
Сохранить в:
| Опубликовано в: : | Respir Res |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4756424/ https://ncbi.nlm.nih.gov/pubmed/26887407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-016-0330-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|